Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Average Rating of “Moderate Buy” from Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has received a consensus rating of “Moderate Buy” from the fifteen research firms that are currently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $173.07.

Several brokerages recently issued reports on JAZZ. Wells Fargo & Company reduced their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They issued a “buy” rating and a $169.00 target price for the company. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Finally, Morgan Stanley lowered their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research note on Friday, July 12th.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $107.14 on Friday. The stock has a market capitalization of $6.76 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 1.45 and a beta of 0.58. The company’s 50-day simple moving average is $109.75 and its 200-day simple moving average is $112.47. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $137.57.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $7,201,000. Victory Capital Management Inc. raised its position in shares of Jazz Pharmaceuticals by 4.3% during the fourth quarter. Victory Capital Management Inc. now owns 136,589 shares of the specialty pharmaceutical company’s stock valued at $16,800,000 after buying an additional 5,614 shares during the last quarter. First Trust Direct Indexing L.P. lifted its position in shares of Jazz Pharmaceuticals by 10.8% in the 4th quarter. First Trust Direct Indexing L.P. now owns 1,778 shares of the specialty pharmaceutical company’s stock worth $219,000 after acquiring an additional 173 shares during the period. Private Advisor Group LLC lifted its position in Jazz Pharmaceuticals by 49.2% in the fourth quarter. Private Advisor Group LLC now owns 2,967 shares of the specialty pharmaceutical company’s stock worth $365,000 after purchasing an additional 979 shares during the period. Finally, Versor Investments LP lifted its holdings in shares of Jazz Pharmaceuticals by 480.9% during the 4th quarter. Versor Investments LP now owns 11,200 shares of the specialty pharmaceutical company’s stock worth $1,378,000 after acquiring an additional 9,272 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.